<DOC>
	<DOCNO>NCT01842607</DOCNO>
	<brief_summary>This multi-centre , open-label long-term safety study 100 milligram ( mg ) mepolizumab administer subcutaneously ( SC ) every 4 week 12 month addition standard care subject severe , refractory asthma history eosinophilic inflammation . Subjects complete either MEA115588 MEA115575 offer opportunity consent study .</brief_summary>
	<brief_title>A Study Determine Long-term Safety Mepolizumab Asthmatic Subjects</brief_title>
	<detailed_description />
	<criteria>French subject : In France , subject eligible inclusion study either affiliate beneficiary social security category . Informed Consent : Prior commence study related activity , subject must able willing provide write informed consent . MEA115588 MEA115575 study completion : Completion doubleblind investigational product treatment MEA115588 MEA115575 . Current AntiAsthma Therapy : Asthma currently treat controller medication ( i.e. , inhale corticosteroid [ ICS ] asthma control medication ) subject controller medication past 12 week . Subjects expect continue controller therapy duration study . Male eligible female subject : To eligible entry study , female childbearing potential must commit consistent correct use acceptable method birth control duration trial 4 month last study drug administration . A serum pregnancy test require female initial Baseline Visit ( Visit 1 ) . In addition , urine pregnancy test perform female prior enrollment , schedule study visit prior injection investigational product , Followup Visit . Hypersensitivity : Hypersensitivity reaction relate study medication MEA115588 MEA115575 lead patient withdrawal . Subjects experience localized injection site reaction need exclude . Health Status : Clinically significant change health status MEA115588 MEA115575 opinion investigator would make subject unsuitable participation longterm study . Malignancy : A current malignancy malignancy develop MEA115588 MEA115575 ( subject localize carcinoma skin resect cure exclude ) . [ Note South Korea : Korean subject diagnosis malignancy within 5 year exclude ] Prior SAE : A study relate SAE MEA115588 MEA115575 assess possibly relate study medication investigator . Pregnancy : Subjects pregnant breastfeeding . Subjects enrol plan become pregnant time study participation . ECG : Baseline ECG clinically significant abnormality show correct QT interval Fridericia ( QTcF ) &gt; =450 millisecond ( msec ) QTcF &gt; =480 msec subject Bundle Branch Block . Smoking status : Current smoker Liver Function : Liver function test meet follow one last treatment visit MEA115588 MEA115575 : alanine transaminase ( ALT ) &gt; =2 x upper limit normal ( ULN ) ; aspartate transaminase ( AST ) &gt; =2 x ULN ; alkaline phosphatase &gt; =2 x ULN ; Bilirubin &gt; 1.5 x ULN ( isolated bilirubin &gt; 1.5 x ULN acceptable bilirubin fractionate direct bilirubin &lt; 35 % Hepatitis Status : Positive Hepatitis B Surface Antigen ( HBsAg ) screen Visit 1 ECG Overread : Clinically significant abnormality identify central overread one last treatment visit MEA115588 MEA115575</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2016</verification_date>
	<keyword>eosinophil</keyword>
	<keyword>mepolizumab</keyword>
	<keyword>SB-240563</keyword>
	<keyword>safety</keyword>
	<keyword>extension study</keyword>
	<keyword>Severe refractory asthma</keyword>
</DOC>